VCBeat Health Contact Us
Home Hansoh Pharmaceutical (03692): Third NDA for XinYue® (Inebilizumab Injection) Accepted by China's NMPA for Generalized Myasthenia Gravis

Hansoh Pharmaceutical (03692): Third NDA for XinYue® (Inebilizumab Injection) Accepted by China's NMPA for Generalized Myasthenia Gravis

May 30, 2025 17:45 CST Updated 17:45
Hansoh Pharma

Pharmaceutical Research, Production, and Sales

HONG KONG, May 29, 2025 (GLOBE NEWSWIRE) -- Hansoh Pharma (03692) announced that on May 29, 2025, the third marketing authorization application for XinYue® (Inebilizumab Injection) was accepted by the National Medical Products Administration (NMPA) for the treatment of adult patients with generalized myasthenia gravis (gMG).